FindTrial
Sign In

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults

A Randomized, Open-label, Two-treatment, Two-period, Two-sequence Crossover Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07521241
Enrollment
52
Registered
2026-04-09
Start date
2026-05-01
Completion date
2026-07-01
Last updated
2026-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Liver Disease (CLD)

Brief summary

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults

Interventions

DRUGAD-230, AD-2301

Oral administration of AD-230 or AD-2301, according to randomized sequence.

Sponsors

Addpharma Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to 64 Years
Healthy volunteers
Yes

Inclusion criteria

* \- Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening visit * Subjects aged 19 years or older and under 65 years at the screening visit

Exclusion criteria

* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration * Other exclusions applied

Design outcomes

Primary

MeasureTime frame
AUClast-24hours to 72hours
Cmax-24hours to 72hours

Countries

South Korea

Contacts

CONTACTSarah Yoon
sryoon@addpharma.co.kr031-891-5576

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 14, 2026